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                                       INTRODUCTION 
                        Sytemic lupus erythematosus is a paradigmatic autoimmune 
disorder, the manifestations of which are protean sparing few organ systems if 
any.
1
 Such diversity is attributed to its etiopathogenesis wherein antibodies to the 
components of cell nucleus have been implicated. One major cause of morbidity 
and utilization of health resources is renal involvement. More than half of the 
mortality in SLE is due to renal involvement.
2-5
  
                         As with SLE, heterogeneity, both clinical as well as histological is 
the hall mark of lupus nephritis. The disease usually is asymptomatic in its earlier 
course thus vigilant screening of SLE patients for renal involvement remains the 
important step in reducing the mortality and morbidity. 
                       Even though recent treatments are effective and have reduced the 
adverse outcomes the therapeutic options are limited and induce toxicities in the 
long term. 
6,7
 Hence there is a need to identify patients who may have a worse 
prognosis so that aggressive treatment can be instituted early.  
                        Prognosis and therefore treatment decisions vary greatly according 
to the clinical and pathological forms of lupus nephritis. 
8-10   
Each individual has a 
unique combination of these. Even though individual factors vary in their impact, 
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the greater the number of factors with worse prognosis, the less the patient is likely 
to respond to therapy and hence needs aggressive therapy. 
                       Considering the above mentioned prognostic factors may help in 
improving clinical decision making regarding the type and intensity of immune 
suppressive treatment for patients with lupus nephritis. 
                      Studies of long term prognosis in lupus nephritis have focused on 
risk factors which are present either at the onset or those that develop during the 
course of the illness. These predict the mortality over subsequent 10 years. The 
results of these studies may vary but they are useful as they inform us about how 
specific manifestations influence the outcome. But these are less helpful in making 
treatment decisions than studies of short term prognosis as short term outcome 
studies are more likely influenced by timely intervention. 
                      In spite of many years of intense investigations controversies 
surrounding the importance of clinical, demographic, laboratory and histologic 
features in predicting renal outcomes continue to evolve as current and recent 
treatments have altered the prognostic significance of these factors that were 
previously considered significant.    
                      Here in this study we have tried to assess the outcomes of lupus 
nephritis in fifty patients and the association of clinical and immunologic profile 
with these outcomes has been studied.  
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                              AIMS AND OBJECTIVES  
 
1. To study the outcomes of lupus nephritis in 50 patients during the study period. 
2. To study the association of demographic, clinical, laboratory, histopathologic 
and treatment profile of these patients with the outcome. 
3. To compare the results with the standard data available. 
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                               REVIEW OF LITERATURE 
   EPIDEMIOLOGY:              
                      Lupus nephritis affects 40-70% of patients with SLE.
11
The frequency 
of  lupus nephritis peaks during the first two years since the onset of SLE and its 
incidence follows a decrescendo pattern reaching a trough after five years of SLE. 
Asymptomatic urine abnormalities like proteinuria or hematuria is seen in half the 
cases. In about 30% nephrotic or nephritic syndrome occurs. Chronic renal 
insufficiency or rapidly progressive glomerulonephritis occur in less than 5% of 
the individuals. 
PATHOGENESIS:  
                     Only a few diseases like lupus nephritis are characterized by  immune 
complexes detected in all four renal components namely glomeruli, tubules, 
interstitium and blood vessels.
12
 Although IgG is the dominant immunoglobulin 
(98%) co-deposits of IgM and IgA are also common. The term ‗full house‘ staining 
is applied when all the three immunoglobulin classes are present. 
                     Intraglomerular inflammation and recruitment of leukocytes are the 
earliest events in kidney that follow immune complex formation and their 
deposition. Activation and proliferation of resident renal cells soon follow the 
initial events. Fibrinoid necrosis occurs due to the destruction of renal cells by 
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necrosis or apoptosis. In the event of lesser injury there is proliferation of 
endocapillary cells and production of extracellular matrix. Rupture of capillary 
wall and even the capsule itself occurs in case of severe injury resulting in 
accumulation of fibrin over basement membrane along with collagen, mononuclear 
cells and epithelial cells in the urinary space resulting in crescentic 
glomerulonephritis pattern. Atrophy and scarring is the end result of protracted 
inflammation. 
                     The histopathology and the intensity of the inflammatory response are 
closely linked to the location of immune complex deposition and formation. 
Mesangial lupus nephritis occurs when immune complexes are deposited in 
mesangium. Focal or diffuse proliferative lupus nephritis with profuse glomerular 
hypercellularity occurs when immune complexes are deposited in the 
subendothelial region. Proliferation of endothelial and mesangial cells hand in 
hand with leukocytic infiltrates is the cause for this hypercellularity the result of 
which is compromised capillary flow and renal function. Membranous 
nephropathy occurs when there are epimembranous (subepithelial) deposits along 
diffusely thickened peripheral glomerular capillary loops and lack of inflammatory 
infiltrates. 
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                    The differences in the composition and properties of the immune 
complexes such as size, specificity, charge and immunoglobulin isotype probably 
explain the diverse morphological expressions of lupus nephritis. An intermediate 
sized, high avidity small immune complex favours a mesangial pattern while large 
sized loads can spill into the subendothelial region. Low avidity, smaller, cationic 
complexes that dissociate and reform in situ favors sub epithelial deposits. 
                   Traditional thinking is that lupus nephritis is a quintessential type III 
hypersensitivity reaction with deposition of immune complexes in the glomeruli 
and subsequent complement activation.
13
 Recently emphasis is also given to the 
significance of local formation of immune deposits.
14 
Positively charged 
nucleosomes are attracted towards the negatively charged sites in the glomerular 
wall. After getting implanted in the glomerular filter these auto antigens form 
immune complexes after reacting with the circulating auto antibodies.  
                   Auto antibodies to normal glomerular constituents like laminin, 
heparan sulfate, type IV collagen are also implicated in another theory of in situ 
immune complex formation. The role of antigen presentation by T cells, activated 
macrophages and Fcγ receptor (FcγR) bearing monocytes are important in 
glomerulonephritis.
15-17
 Mice deficient in FcγR are immune to development of 
glomerulonephritis but not to immune complex deposition.
18
 
7 
 
GENETICS: 
                  This can be divided in to HLA and non HLA genes. HLA genes 
implicated in lupus nephritis are HLADRB1*1501/DQB1*0602, DQB1* 0201, 
DQB1*0301, DR2/DR3. Homozygous deficiencies of early complement 
components have also been implicated.
19
 
COMPLEMENT SYSTEM : 
                   The role of complement system in the pathogenesis of lupus nephritis 
cannot be under estimated. Presence of complement activation factors in tubules, 
glomerulus, interstitium and urine provides support for this. Though classical 
component pathway deficiency is viewed as a predisposing factor for lupus 
nephritis, great majority of patients have intact alternative especially lectin 
pathway. Evidences favouring the role of complement pathway include findings 
that an inhibitory anti-C5 mAb hinders the onset of glomerulonephritis in the 
(NZB X NZW) F1 model of SLE. The fact that fB-/- and fD-/-MRL/lpr mice are 
immune from lupus nephritis also underscores the importance of alternate pathway. 
                    Though role of complement activation is traditionally restricted to 
glomerular disease, additional roles in tubulointerstitial inflammation and 
proteinuric states have also been suggested. When complement activation 
components enter the urinary space after a break in basement membrane they are 
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capable of being activated since the tubular epithelium lacks complement 
regulatory proteins.  
ROLE OF ANTI-ds DNA: 
                     Anti-ds-DNA antibodies are present in about 60% of patients with 
SLE. Specifically they are associated with nephritis which has the strongest 
correlation with it.
20
 Lot of evidence suggests the role of DNA-anti DNA 
complexes in the pathogenesis of LN.
21
 This includes detection of anti-DNA 
antibodies in the kidneys, free DNA in the plasma, alterations in the serum 
concentrations of anti DNA antibodies and complement. The theory of molecular 
mimicry has also been implicated wherein anti ds DNA may react with glomerular 
and mesangial target antigens such as alpha actinin, a matrix protein. Not all 
patients with high anti ds DNA develop nephritis. Anti-DNA measurements may 
help in monitoring disease activity. Sometimes anti-DNA and complement (C3, 
C4) levels vary reciprocally over time.
22,23
 ELISA and Crithidia luciliae 
kinetoplast staining assay detect low affinity interactions whereas Farr assay, 
which detects high-affinity antibodies, may predict disease activity more 
accurately and may increase 10 or more weeks before a flare.  
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ROLE OF APS NEPHROPATHY: 
                   Anti-phospholipid antibodies  are implicated in the pathogenesis of   a 
unique type of vascular nephropathy (APSN).Features of  APSN are present in 
20% to 30% of patients with SLE.
24 
They are fibrous  occlusions of 
arteries/arterioles, organizing thrombi with recanalisation, thrombotic 
microangiopathy,  focal  cortical atrophy and chronic lesions such as fibrous 
intimal hyperplasia.
25, 26
 
 CLINICAL FEATURES: 
                    Lupus nephritis is usually asymptomatic unless it is advanced 
nephrotic syndrome or renal failure. It is usually discovered during a routine 
evaluation. Proteinuria, presence of urinary casts, hematuria, pyuria, increased 
serum creatinine and hypertension are the   features    most    commonly     seen .  
Specifically the revised criteria for classification for SLE includes a) Persistent 
proteinuria > 0.5 g per day or > than 3+ if  quantitation not   performed,   OR 
b) Cellular casts: red cell, hemoglobin, granular, tubular, or mixed as evidence of 
renal disease.Hematuria (>5 RBCs/HPF),pyuria (>5WBCs/HPF) in the absence of 
infection and raised serum creatinine concentration have also been recognized as 
the renal manifestations. Hence urine analysis must be performed regularly in 
addition to  serum creatinine. 
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 RENAL BIOPSY 
                   Renal biopsy is necessary to identify the type of kidney involvement as 
patient management is determined based on it.
27,28
 Most patients with lupus 
nephritis have abnormal renal biopsy either on light microscopy or special 
techniques like immunofluorescence or electron microscopy.  
                      Renal involvement is not only limited to glomerulonephritis but may 
also be due to interstitial nephritis, tubular disease, vasculitis, arteriolosclerosis, 
thrombotic microangiopathy, and lupus vasculopathy. There may be changes 
secondary to co-morbidities such as human immunodeficiency virus (HIV) 
infection. A semi quantitative analysis of specific histologic features based on a 0-3 
scale) is included into the elements of the activity and chronicity indices.  
                   The International Society of Nephrology/Renal Pathology Society 
revised the earlier World Health Organization classification in 2003 for a better 
description and standardization of the lesions seen on biopsy. The classification is 
based on the changes observed on light microscopy, immunofluorescence staining, 
and electron microscopy.
29
 In a study of 46 japenese patients Yakohama et al found 
that ISN /RPS 2003 has better prognostic value.
30
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INDICATIONS FOR RENAL BIOPSY IN LUPUS NEPHRITIS 
 INITIAL BIOPSY (before treatment) 
      Nephritic urine sediment (glomerular hematuria and cellular casts). 
      Glomerular hematuria with proteinuria >0.5 to 1.0 gm/day. 
      Glomerular hematuria with proteinuria <0.3 to 0.5 gm/day and low C3 and/ 
       or positive anti-ds DNA. 
      Proteinuria >1.0 to 2.0 gm/day (especially if C3 is low and/or positive 
       anti-ds DNA). 
REPEAT BIOPSY (during or after treatment) 
     Unexplained worsening of proteinuria (>2 gm/day increase if non nephrotic 
     at baseline, or >50% increase if nephrotic). 
    Unexplained worsening of renal function (reproducible ≥30% increase in 
    serum creatinine). 
     Persistent glomerular hematuria with proteinuria >2 gm/day or proteinuria 
     >3 gm/day (especially if C3 is decreased). 
     Nephritic or nephrotic flare. 
 
According to recent EULAR/ ERA-EDTA guidelines any renal involvement is 
considered an indication for renal biopsy. 
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ACTIVITY AND CHRONICITY INDICES * 
 
Activity index (lesions are scored 0-3 with maximum score 24 points) 
 * Hypercellularity: endocapillary proliferation compromising glomerular 
capillary loops 
 * Leukocyte exudation: polymorphonuclear leukocytes in glomeruli 
 * Karyorrhexis/fibrinoid necrosis (weighted ×2): necrotizing changes in 
glomeruli 
 * Cellular crescents (weighted ×2): layers of proliferating epithelial cells and 
monocytes lining Bowman capsule 
 * Hyaline deposits: eosinophilic and PAS-positive materials lining (wire loops) 
or filling (hyaline thrombi) capillary loops 
 * Interstitial inflammation: infiltration of leukocytes (predominantly 
mononuclear cells) among tubules 
 
Chronicity index (lesions are scored 0-3 with maximum score 12 points) 
 * Glomerular sclerosis: collapse and fibrosis of capillary tufts 
 * Fibrous crescents: layers of fibrous tissue lining Bowman capsule 
 * Tubular atrophy: thickening of tubular basement membranes, tubular 
epithelial degeneration, with separation of residual tubules 
 * Interstitial fibrosis: deposition of collagenous connective tissue among 
tubules 
 
( * Scored on a scale of 0-3 representing either (a) absent, mild, moderate, and 
severe lesions or  (b) the presence of lesions in none, <25%, 25% to 50%, and 50% 
of  glomeruli , respectively.) 
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Table 1-  ISN/RPS CLASSIFICATION OF LUPUS NEPHRITIS  
                    
Class I Minimal mesangial lupus nephritis 
Normal glomeruli by light microscopy, but mesangial immune 
deposits by immunofluorescence 
Class II Mesangial proliferative 
Purely mesangial hypercellularity of any degree or mesangial matrix 
expansion by light microscopy, with mesangial immune deposits 
A few isolated subepithelial or subendothelial deposits may be 
visible by immunofluorescence or electron microscopy, but not by 
light microscopy 
ClassIII Focal lupus nephritis 
Active or inactive focal, segmental, or global endocapillary or 
extracapillary glomerulonephritis involving <50% of all glomeruli, 
typically with focal subendothelial immune deposits, with or 
without mesangial alterations 
 
Class IV 
Diffuse lupus nephritis 
Active or inactive diffuse, segmental or global endocapillary or 
extracapillary glomerulonephritis involving ≥50% of all glomeruli, 
typically with diffuse subendothelial immune deposits, with or 
without mesangial alterations. This class is divided to diffuse 
segmental (IV-S) lupus nephritis when ≥50% of the involved 
glomeruli have segmental lesions and diffuse global (IV-G) when 
≥50% of the involved glomeruli have global lesions. Segmental is 
defined as a glomerular lesion that involves less than half of the 
glomerular tuft. This class includes cases with diffuse wire loop 
deposits but with little or no glomerular proliferation 
 
Class V 
Membranous lupus nephritis 
Global or segmental subepithelial immune deposits or their 
morphologic sequelae by light microscopy and by 
immunofluorescence or electron microscopy, with or without 
mesangial alterations 
Class V nephritis may occur in combination with class III or class IV, in 
which case both will be diagnosed 
Class V nephritis may show advanced sclerotic lesions 
Class VI Advanced sclerotic lupus nephritis 
≥90% of the glomeruli globally sclerosed without residual activity 
14 
 
                   Renal  biopsy may show hematoxylin bodies, the tissue equivalent of 
LE cell phenomenon. Mesangial lupus nephritis characterized by the accumulation 
of immune complex deposits within the mesangium (class I)  and its futher 
progression in to mesangial hypercellularity (class II) are at the milder end of the 
spectrum of the renal lesions. Most people with mesangial lupus nephritis  are 
clinically silent and respond well to renoprotective therapies even without 
aggressive immunosuppressive regimens though on occasions they may have 
severe renal involvement and validate aggressive therapy. Lupus nephritis is 
further classified as focal or diffuse  depending on the percentage of glomeruli 
involved with subendothelial deposits,  i.e. class III (<50% involved)  and class IV 
( ≥50% glomeruli involved) respectively. They are further described according to 
the chronicity of the lesions. Membranous lesions (class V) are characterized 
mainly by subepithelial deposits.They may also have mesangial involvement. 
Advanced sclerosis (class VI) is the end stage or ―burnt out‖ phase of lupus 
nephritis. Lupus vasculopathy is characterized by the presence of hyaline thrombi 
within the arteriolar lumen and/or intralobular arteries. Tubulointerstitial 
disease involves tubular basement membrane atrophy. Other findings that may also 
be seen in lupus are lupoid nephrosis, focal segmental glomerulosclerosis, IgM 
nephropathy and amyloidosis. 
31
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                                 EVALUATION  
ASSESSMENT OF RENAL INVOLVEMENT: 
                  The basic assessment of renal function requires screening for 
proteinuria, hematuria, leukocyturia and nitrates to check for infections using a 
urine dipstick. While assessing hematuria other conditions like infections, calculi 
and menstrual blood loss must be excluded. Urine casts still remain an important 
indicator of active renal disease. Analysis of a 24 hr urine specimen is more useful 
than a urine dipstick or serum creatinine. Protein/creatinine ratio or albumin 
creatinine ratio and glomerular filtration rate (GFR) are also becoming important 
tools especially in clinical trials as these require little patient cooperation and are 
more robust measurements. Renal biopsy remains the best way to distinguish renal 
activity from damage and to establish the type of renal involvement. 
                     The use of serological tests in assessing lupus activity has long been 
debated.
32
  Anti ds DNA antibodies are present in 60% of lupus patients making its 
measurement useful  only in those with positive antibodies. Usually the levels rise 
during the development of a flare. But it may fall during peak clinical activity 
because of tissue deposition. Changing levels of ds DNA antibodies must be 
viewed with caution especially before reducing therapy. Decreasing levels of 
complements C3 or C4 are usually the forerunner of a renal flare. So are the raising 
levels of complement degradation products C3d or C4d. 
16 
 
 
                          MONITORING DISEASE ACTIVITY 
URINALYSIS:  
                   Urinalysis is the most useful method to detect and monitor disease                           
activity in lupus nephritis. The urine sample must be fresh, early morning, mid 
stream, clean catch and non refrigerated. Presence of hematuria (usually 
microscopic) indicates inflammatory glomerular  or tubulointerstitial involvement. 
Granular and fatty casts indicate proteinuric states while cellular casts involving 
RBCs, WBCs or mixed pattern are indicators of nephritic states. Severe glomerular 
and tubular ongoing disease can cause ‗telescopic urine sediment‘ i.e. containing 
full range of cells and casts. Resolution of urine sediments is a feature of renal 
remission provided it is sustained. Reappearance of cellular casts when associated 
with proteinuria is a very early predictor of renal flare and may precede anti ds 
DNA titers or decreased complement levels. Spot urine protein creatinine ratio is 
an easy method to estimate the severity of proteinuria. It could be used in between 
24 hr collections to roughly estimate the response to therapy.  
 
RENAL FUNCTION : 
                    Serum creatinine  is a practical test but as it depends on muscle mass, 
age and GFR, it is relatively an insensitive early indicator of abnormalities in 
17 
 
GFR.Rather than absolute values it is the change that is important especially 
significant (20-30% increase).Creatinine clearance is being utilized only rarely 
since it overestimates the true GFR. 
 
ASSESEMENT OF PROGNOSIS: 
                  There are many demographic and clinical variables which affect the 
outcome. In general black race,anemia,antiphospolipid syndrome, azotemia, failure 
to respond to initial therapy and flares with deteriorating renal function are 
associated with poor outcome.   
 
FACTORS ASSOCIATED WITH ADVERSE PROGNOSIS  
DEMOGRAPHIC: Black race, limited access to health care, male sex, children). 
CLINICAL:            Hypertension; severe extra renal disease affecting major 
organ; failure to achieve or marked delay (>2 years) to renal remission; multiple 
flares of lupus nephritis; pregnancy. 
LABORATORY:   Nephritic urinary sediment, azotemia; anemia; 
thrombocytopenia; antiphospholipid antibodies; thrombotic microangiopathy; 
hypocomplementemia (especially falling levels); high anti-DNA (especially 
rising titers); persistent severe nephrotic syndrome. 
HISTOLOGIC:      Proliferative glomerulonephritis (WHO class III-IV); mixed 
18 
 
membranous (V) and proliferative (III-IV) glomerulonephritis; cellular 
crescents; fibrinoid necrosis; very high activity index; moderate-to-high 
chronicity index; combinations of active (cellular crescents) and chronic 
histologic features (interstitial fibrosis); extensive subendothelial deposits. 
 
MORBIDITY AND MORTALITY: 
                     Lupus nephritis poses significant morbidity and mortality. In some 
studies it was found that the health cost of patients with lupus nephritis was twice 
higher than their fellow lupus patients without it. The major cause of morbidity 
other than SLE and nephritis include those due to long term corticosteroid use such 
as infections and osteoporosis. 
                     The five year survival of LN has improved from 17% for class IV LN 
in 1950s to82% in 1990s. The early mortality was due to sepsis and active SLE 
while late mortality was due to cardio vascular events and thrombosis. 
33. 
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TREATMENT 
                    Recently European League Against Rheumatism-(EULAR)/ERA-
EDTA has published guidelines for treatment of adult and pediatric lupus 
nephritis
34
 wherein the  ultimate aims of treatment are preservation of renal 
function,  prevention of disease flares, avoidance of  drug related complications, 
and provision of good quality of life. Treatment must aim for complete renal 
response. 
INDUCTION: 
                   For patients with classIII or class IV(± class V)-MMF 3g/day or low 
dose IV cyclophosphamide together with steroids. 
                   In patients with poor prognostic features monthly cyclophosphamide 
can be given (0.75-1 gm/m
2
).This should be combined with three pulses of IV 
methylprednisolone (500-750mg) followed by oral steroids. (0.5mg/kg/day of 
prednisolone to be given  over four weeks and gradually tapered to less than 10 mg 
/day by six months. 
                   In patients with class V LN who have nephrotic range of proteinuria 
MMF 3g/day over six months along with steroids is the therapy of choice. As an 
alternative therapy azathioprine or cyclosporine can also be given in certain 
patients who do not have poor prognostic features. 
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MAINTENANCE : 
                   Maintenance therapy is with MMF 2g/day or azathioprine 2mg/kg/day 
along with low dose steroids. In those patients who were initially treated with 
MMF it should be continued. If pregnancy is desired azathioprine may be an 
alternative. In refractory disease treatment can be switched between the drugs. 
ADJUNCTIVE TREATMENT 
35
 
        ACE inhibitors in patients with hypertension and proteinuria. 
        Statins for dylipidemia (target LDL 100 mg%).  
        Chloroquin for decreasing renal flares and to reduce cardiac and kidney 
damage. 
       Aspirin for patients with APS. 
       Vitamin D and Calcium supplements. 
       Treatment  of comorbidities. 
       Anti coagulants for patients with nephrotic syndrome (albumin< 2g%) . 
 
LUPUS NEPHRITIS IN PREGNANCY 
                   Pregnancy may be considered if lupus is inactive and Urinary PCR <50 
mg/mmol for 6 months, with a GFR > 50 ml/min. Drugs that can be used include 
hydroxychloroquine,low dose methylprednisolone, azathioprine and calcineurin 
inhibitors. Treatment intensity should not be reduced in anticipation of pregnancy. 
21 
 
Aspirin should be used to reduce the risk of pre-eclampsia. B.P should be treated 
with nifedepine or labetolol. Complement levels should be measured to 
differentiate lupus nephritis flare from preeclampsia.
36, 37
  
                  From the above discussion it is clear that lupus nephritis is 
characterized by immune complex formation, varied clinical manifestations and 
multiple laboratory abnormalities with frequent exacerbations. Renal involvement 
being very common is a major determinant of the disease course. 70-80 % of SLE 
patients have one or the other form of renal involvement and majority of them 
present with class IV lupus nephritis. Worldwide survival rates in LN have 
improved remarkably during successive years due to early diagnosis. Better 
awareness of risk factors and better treatment modalities also have contributed to 
this improved prognosis.  
                   Studies done in yester years (in 1970s) by Ester and Christian
38 
showed 
an estimated five year survival rates for patients with lupus nephritis of 50% as 
against 75% for whole SLE series. The rates for severe kidney disease was even 
lower,68% for class III and 28% for class IV and V. But in these series patients 
were being treated only with steroids as immunosuppressants were not widely 
available at that time. In 1980s and 1990s survival rate became much better around 
60-65%.
39 - 41
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                    As reported by Korbet et al achievement of remission and the type of 
treatment given also has considerable effect on outcome.
42
 The survival rate for 
patients in his series was 95% at 5 yrs. In this series complete remission was 
achieved in 43% and time taken to achieve complete remission was 18 months. 
Stable renal function, lower chronicity index and white race were positive 
predictors of remission. 
                   A study conducted in Europe by Houssiau & colleagues 
43 
has reported 
similar outcomes for patients receiving the conventional NIH Vs ELNT protocol. 
                   According to James Tumlin of  Emory  university Atlanta 
44, 45
 poor 
prognostic factors include persistent anaemia, severity of disease ,time to treatment 
and duration of remission. In another study in patients
  
treated with intravenous 
cyclophosphamide an age at diagnosis of < 29 years was  associated with a higher 
risk of progression to LN in 5 years. 
46
 Also an advanced chronicity index (> 3) at 
biopsy and a delay to treatment of  greater than 5 months were linked to worse 
outcomes. Patients who did not have a flare-up of their disease had only 25% risk 
of doubling their serum creatinine in 5 years compared to 75% risk in patients who 
experienced flare-ups in the observation period. 
                    On the contrary Austin 
 
and colleagues, in 1994 reported  that , female 
sex, age > 30 years, black race, the presence of focal necrosis, proteinuria, 
23 
 
crescents,lower C3 (< 76 mg/dL) following therapy and hematocrit of < 26% were 
associated with a worse prognosis.
47
  
                   Renal biopsy is very important in terms of diagnosis, therapeutics and 
prognosis. Presence of cellular crescents, interstitial fibrosis was associated with 
increased risk of progression.
48
 
                  Differences in outcomes of patients with lupus nephritis with and 
without renal biopsy was studied in a 5 year comparative study by Jakez Ocampo J 
published in 2004.
49
 This study aimed at comparing the  5 year course of patients 
treated without biopsy with another group with histologic evidence of diffuse 
proliferative glomerulo nephritis, each group consisting of 30 patients. The no 
biopsy group had strong clinical and laboratory suspicion of proliferative 
glomerulonephritis. In this group biopsy was not done either because of medical 
contraindication or patient‘s refusal. The biopsy group consisted of patients with 
histologic diagnosis of diffuse proliferative glomerulonephritis. Patients were 
regularly followed up from the onset up to 60 months. Results showed  that 
although both groups had deterioration of renal function, no significant differences 
were found in treatment, outcome, survival, renal function tests or development of 
renal failure .This study demonstrates that experience in the management of lupus 
nephritis along with clinical and laboratory data provide enough information to 
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adequately treat patients with proliferative glomerulonephritis even without  renal 
biopsy.  
                   Studies conducted across the world assessing the outcomes have given 
varying results. In a study conducted by Senija et al 
50
 assessing the long term 
outcome of patients with lupus nephritis, complete remission was achieved in 
60.9%, partial remission was accomplished in 29.2% pts during a mean period of 
follow up of 10.9 yrs.± 4 yrs. This complete remission was sustained for 30.1± 
19.1 months and during follow up 29.3% patients developed at least one nephritic 
flare. 
                   The very long term prognosis of Lupus nephritis was also analyzed by 
Bono L  et al in a study published in Quarterly Journal of Medicine in 1999.
51
 In 
this study 110 patients were analyzed over a median follow up of 15 years. Out of 
them 40 were dead and 70 alive. Among those alive 38 % had normal renal 
function and urinalysis. 62% had persistent proteinuria and 18% had decreased but 
stable renal function. But in this study the predictive power of clinical and 
histological parameters was not assessed in detail and simple univariate analysis 
revealed that there was no correlation between any parameters at onset including 
GFR and survival.  
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                  The factors which influence the outcome of ESRD in LN are 
multifactorial. According to TaK Mao Chan 
52
 they can be divided into  disease 
related, treatment related, patient and community related and others.   
Disease related   Extra renal disease activity 
                           Severe irreversible organ damage 
                           Anti Phospholipid Syndrome 
                           Repeated major flares. 
Treatment related  
                           Efficacy of immunosuppression 
                           Timeliness of treatment. 
                           Acute and chronic adverse events related to treatment. 
Patient and community related 
                            Ethnicity –genetic variations in progression to renal failure 
                            Geographic variations in health care system and economics. 
                              Socio economic factors that affect access to health services and  
education. 
 Others:              Could be related to disease  or  to treatment like long term 
vascular disease. 
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                   In a study by Faurschou  et al 
53 
where the authors analyse the 
outcomes of 91 patients with biopsy proven LN over a median follow up of 6.1 
yrs,the cumulative incidence of ESRD after 1,5, and 10 yrs was 3.5%, 15% and 
17% respectively. In this study they identified duration of nephritis symptoms 
greater than six months prior to  biopsy as the strongest independent risk factor for 
ESRD.  Others being serum creatinine greater than 140 µmol/L,marked 
proteinuria,  smoking, male sex, higher activity/chronicity index, hypertension, 
age, race, ethnicity, low response to initial treatment, frequency of flares, socio 
economic factors, treatment modality, low hemoglobin/hematocrit, 
thrombocytopenia and histologic features of  diffuse proliferative glomerulo 
nephritis. This study emphasizes the fact that the timing of renal biopsy and 
treatment are critical factors influencing the prognosis of LN. 
                    Specifically in a recent study published in 2011 in the journal Arthritis 
Care and Research by Hseih, tubulointerstitial inflammation and not glomerular 
inflammation predicted progression to renal failure.
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                    Others like Estadile 
55
also have shown that early biopsy and treatment 
is an important prognostic factor. Mortality in LN has reduced compared to earlier 
decades. Reasons include introduction of immunosuppression in addition to 
steroids and adjuvant treatment with ACE inhibitors.   
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                   The impact of relapses on the final outcome was studied by M El 
Hachmi Et al. 
56
 Results published in 2003 concluded that renal relapses are 
common in patients with lupus nephritis and have a negative impact on outcome 
but cannot be always predicted. Even years after initial episode regular blood and 
urine examinations are necessary the importance of which was stressed in this 
study. 
                   So tight control, frequent monitoring,early diagnosis and  treatment  
are potent ways to improve the outcomes of LN. 
                    The relationship between clinical renal disease and histologic class 
was analysed in a study by Gladman et al published in Oxford Journal Of medicine 
in 1989.
57
 In this study there was no correlation between clinical disease and renal 
histology. On the contrary a landmark study by Austin et al 
47
 discussed the role of 
clinical and histological data in the prediction of renal outcomes in patients with 
severe lupus nephritis. The study was conducted in Kidney Disease section, 
National Institute of Health, Maryland, USA. In this study 65 patients with severe 
lupus nephritis treated with intravenous cyclophosphamide or methyl prednisolone. 
Five clinical features were associated with increased risk of doubling of serum 
creatinine – age more than 30 yrs, black race, hematocrit < 26 %, s.creatine more 
than 2.4 mgm%, low c3 < 76mg%.After statistical analysis hematocrit, s.creatinine 
and race were the strongest set of independent clinical predictors of outcome. 
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Other demographic and clinical features like age and C3 levels did not correlate 
significantly to outcome prediction when compared to the above mentioned 
variables. Renal biopsy offered additional information in that patients with severe 
active and chronic changes on biopsy were at increased risk of developing renal 
failure. They concluded that outcome prediction based on clinical factors was 
significantly enhanced by adding pathology data.    
                     The importance of early diagnosis and treatment was also stressed by 
Fiehn et al in 2003.
58
 In this study which compared outcomes during successive 
decades earlier diagnosis and treatment led to better outcomes. 
                   The correlation between clinical and pathological findings was also 
studied by Neshad ST and Sepaskhah R at Shiraj medical school, Iran over a 
period of five years.
59
  The study was published in 2008.In this retrospective study 
144 patients were analyzed for their clinical features, biopsy class and lab 
parameters. Edema, hypertension, low serum albumin, increased proteinuria and 
poor renal function were associated with a worse histologic class .It was concluded 
that there is a correlation between histologic classification and some of the lab and 
clinical findings. 
                   Another study from Iran by Ataei N et al
60
  in 2008 dealt with 
outcomes of LN in the Iranian children and the prognostic significance of certain 
features. The aim of this study was to correlate histopathological features and 
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outcomes of children with lupus nephritis. In this retrospective study 58 children 
with biopsy proven LN were followed up between 1989&2005. 58.6% patients had 
class IV lupus nephritis. The five year survival rate was 82.5% and specifically 
75% in class IV lupus nephritis group. The investigators could not detect any 
independent predictor of poor outcome including renal histology by multivariate 
analysis.   
                    Reviewing the Indian literature, the long term outcome of lupus 
nephritis in Indians has been studied by Dhir V et al 
61 
which analyses the long 
term outcome of patients studied retrospectively over a period of 20 years at a 
single center. Here the primary outcome measure was chronic renal failure or death 
and secondary outcome was end stage renal disease or death. In this study of 188 
patients with lupus nephritis, no difference in survival was observed based on 
histologic class. Risk factors for poor outcome were hematuria, hypertension, 
creatinine level, low complement, major infection. There was a high rate of 
infections. It was concluded that with standard immunosuppression the outcome of 
lupus nephritis in Indians is reasonable. 
                     In a very recent study of eastern Indian patients, short term outcome 
of 86 cases of proliferative LN was studied .
62
   64% had CR or PR at one year and 
14% were treatment refractory. In another study among south Indian patients 82% 
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of class IV achieved CR in a time of 15 months.
 63
 In another study of south Indian 
patients 69% achieved CR or PR at 15.8 months while 31%were refractory.
 64
 
                     Among the pediatric patients in India Hari et al 
65
 from Department of 
Pediatrics AIIMS, has analyzed the outcome of lupus nephritis in Indian children 
in a study published in Lupus 2009. This study analysed the clinicopathologic 
features, treatment and outcome of 54 Indian children. Of the 39 patients who were 
followed-up   84.6% achieved complete or partial remission, whereas six (15.4%) 
were refractory to therapy. Three year survival rate was 88% .There was no 
relation of gender, age of onset, presence of hypertension, haematuria and 
proteinuria,  glomerular filtration rate, renal biopsy and response to therapy to the 
final outcome of death or ESRD. Patient survival rate was lower compared with 
the developed countries but similar to developing countries. Serious infections 
were an important cause of mortality.  
                    In another study published in 2008 from CMC Vellore by  Indira 
Aggarwal  et al
66 
where 70 children were analyzed for clinical profile, treatment 
and outcome of SLE, 77.1% had renal involvement and were followed up.The 
outcomes were defined as i.Remission (normal urinalysis, B.P, s.creatinine, no 
extra renal symptoms), ii. Active disease (proteinuria >0.5g/day, hypertension, 
extra renal features, microscopic hematuria >5 RBC‘s /HPF) , iii) Death and iv) 
Lost follow up. On follow up for 18.8 months 70 % achieved remission, 7.5 % had 
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active disease, 7.5% died and 15% lost follow up. There was no correlation 
between gender, age below 10 years, presence of hypertension, impaired renal 
function or anemia with renal histopathology. Gross hematuria was significantly 
associated with more severe renal histopathology. Nephrotic syndrome at 
presentation had no association with adverse outcomes. 
                   A study analyzing the sex differences in Indian patients with lupus 
nephritis was published in 2008 by Soni SS et al. 
67
 This study of 238 patients 
compared clinical features, lab investigations and histology in males suffering from 
lupus nephritis with females. The study concluded that renal dysfunction and 
activity indices were higher in males than females and the difference was 
statistically significant.  
                   In another study published by Murali et al 
68
 from CMC vellore, 
prognosis, survival and life expectancy was analyzed in 98 patients with SLE. Here 
renal involvement was a poor prognostic factor with proteinuria (>0.5g/day) 
carrying a 50% reduction in life expectancy. But there was no correlation between 
disease activity at onset and outcome. 
                    The importance of race as a factor influencing the short term outcome 
was analyzed in a cohort of 44 patients consisting of African American ethnicity 
by Lau KK et al in 2006. 
69
 African American ethnicity has been considered to be a 
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poor prognostic factor in adult patients with severe lupus nephritis. In this study, 
consisting predominantly of children of African American ethnicity, 23% achieved 
complete remission and 48% had partial remission. It was concluded that the 
clinical presentation and short term outcomes did not differ from the studies with 
predominantly Caucasians. 
                     From the foregoing discussion it is apparent that studies conducted 
across the world regarding the association of clinical profile with outcomes in 
lupus nephritis have given conflicting results. Hence this study was undertaken to 
analyze the same in patients from our center.  
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                        MATERIALS AND METHODS 
SETTING                                        Rheumatic Care Center 
                                                          Rajiv Gandhi Government General Hospital 
                                                          Madras Medical College 
                                                         Chennai 
STUDY DESIGN                           :Prospective analytical study 
PERIOD OF STUDY                     Two years from ethical committee  
                                                          approval 
ETHICAL COMMITTEE    
APPROVAL                                   :Attached  
CONSENT                                     :Informed written consent was obtained fro 
                                                          every patient  after explaining  about the   
                                                          details of the study in their native language.                                                                 
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SELECTION OF SUBJECTS         :50 adult cases of new onset lupus nephritis 
                                                              satisfying the inclusion and exclusion    
                                                              criteria 
INCLUSION CRITERIA                :Adult SLE patients who satisfy the 1997   
.  revised American College of Rheumatology 
  classification criteria 
 70  
with new onset 
  lupus nephritis. 
EXCLUSION CRITERIA               :1.Childhood lupus nephritis 
                                                             2.End stage renal disease  
                                                            3.Relapsed lupus nephritis 
                                                            4.Other causes of chronic kidney disease 
LIMITATIONS OF THE STUDY                             
                      1. Due to technical and financial constraints anti dsDNA antibody, 
ACL antibody and C3, C4 levels could be measured only in few patients. 
                    2. LAC assay was not done in any patient due to laboratory 
constraints. 
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                      3. Not all patients could be followed up and in one patient outcome 
could not be assessed. 
                    4. Biopsy was not done in three patients. 
                    5. The study was only a short term outcome study. 
                      6. Activity /chronicity index was available only for a few patients. 
Hence no attempt at correlating these indices with final outcome was made. 
  METHODS  
                      Selected demographic, clinical, laboratory and histopathologic data 
were obtained from the patients and recorded in a proforma (enclosed in annexure).  
I. SOCIO DEMOGRAPHIC DATA  -Age, sex 
II.CLINICAL DATA                            -Weight, duration , presenting symptoms, 
extra renal system involved, SLEDAI, BP, co morbidities, time taken to achieve 
complete remission, duration of follow up. 
III. LABORATORY DATA                 -Hemogram, urinalysis, blood sugar, RFT, 
LFT,lipid profile, ANA (indirect immunofluorescence  method),anti ds DNA 
(ELISA) , ACL (ELISA), C3 and C4 (radial immunodiffusion). 
IV. IMAGING                                    -Ultrasound abdomen was done. 
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V.HISTOPATHOLOGIC DATA     -Renal biopsy was done by percutaneous 
needle biopsy technique at Department of Nephrology and sent to the pathologist 
for reporting of classification and analysis by light, electron and 
immunofluorescent microscopy. 
                    They were treated with one of the following drugs for induction – 
cyclophosphamide  (ELNT or NIH protocol), MMF or azathioprine. They were 
periodically followed at 3, 6 and 12 months intervals. Outcomes were analyzed at 
the end of study period. 
STATISTICAL METHODS 
                    Statistical analysis was made using SPSS 20 software. Statistical 
methods used include independent samples test, multi step logistic regression 
analysis, chi squared test and correlation coefficients. A p value of  < 0.05 was 
considered statistically significant. 
                  DEFINITIONS USED IN THIS STUDY 
COMPLETE RESPONSE: Urinary protein/creatinine ratio < 0.5g/24 hrs and 
normal or near normal GFR (within 10% of normal GFR). 
 PARTIAL RESPONSE: More than 50% reduction in proteinuria with normal or 
near normal GFR. 
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IMPROVED:  Any reduction in proteinuria with normalization of GFR. 
REFRACTORY: Complete response not achieved by 2 years or partial response 
not achieved by 6-12 months or improvement not achieved within 3 to 4 months. 
FLARE  
NEPHRITIC FLARE: Increase in s.creatinine by >30 % or decrease in GFR by 
>10% and active urinary sediments (RBCs >10 /HPF). 
NEPHROTIC FLARE: Doubling of UPCR to more than 1g/day after CR or 
UPCR to more than 2g/day after PR. 
END STAGE RENAL DISEASE: GFR <15 mL/min/1.73 m2, requiring 
permanent renal replacement therapy (RRT). 
GLOMERULAR FILTRATION RATE: As calculated by Cockroft-Gault 
formula.    
        {140-age X body weight in kg / 72 X serum creatinine } X 0.85 (if female) 
HYPERTENSION: According to the Joint National Committee on prevention, 
detection, evaluation, and treatment of high blood pressure (JNC 7)
71
 guidelines. 
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SLEDAI:  Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)
72
 An 
objective validated global scale to assess the overall disease activity. It contains 24 
items and a total score of 105.  
NIH PROTOCOL : Monthly induction pulses of cyclophosphamide at a dose of 
0.75- 1gm /m
2
 for seven months followed by quarterly pulses for two years beyond 
remission. 
ELNT PROTOCOL: Fixed fortnightly pulses of 500 mg cyclophosphamide (6 
pulses ) followed by azathioprine or MMF. 
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                                         PATIENT PROFILE 
     A total of 50 patients were enrolled as part of the study and followed up for a 
period of 2 years (Mean : 17.3 months ;range :1week-24months). Among these 
forty four were females and six were males. The mean age of the patients was 
25.44 years±7.21.The range of age was 16- 47 years. 
                                              Table 2 
 
                             
 
 
                                              Figure 1     
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6
Sex Distribution
FEMALES
MALES
1 NUMBER OF CASES 50 
2 FEMALES 44 
3. MALES 6 
4. MEAN AGE 25.44 YRS 
5. STANDARD  DEVIATION 7.21 
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                                     FINAL OUTCOME 
The final outcome of these fifty patients were as follows.                                                   
                                  Table 3 
OUTCOME NUMBER PERCENTAGE 
COMPLETE RESPONSE 32 64% 
PARTIAL RESPONSE 2 4% 
IMPROVED 4 8% 
REFRACTORY 6 12% 
DEATH 2 4% 
LOST FOLLOW UP 3 6% 
OUT COME NOT ASSESSED 1 2% 
 
                                   Figure 2 
 
Three patients lost follow up and in one patient the outcome could not be assessed 
as the patient was not willing for biopsy and was irregular in follow up. 
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                             AGE DIFFERENCES IN OUTCOME 
         The mean age of patients who achieved complete response was 25.34 years 
(16-47). The mean age of patients who were refractory or dead was 28.75 (range 
20-41). On an average, patients who achieved complete response were 3 years 
younger than those who remained refractory or died. On multistep logistic 
regression analysis age emerged as an important risk factor influencing the final 
outcome with p value of 0.047. 
 
 
                                                  Figure 3 
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                           GENDER DIFFERENCE IN OUTCOME  
Total number of females was 44 and males 6.The mean age of females was 25.27 
and 26.67for males ( p value for the two samples 0.2529) . 
 
                           Table 4   
 
 
 
 
 
        There is no statistically significant difference between the two groups hence 
both sexes were matched equally for age. 
                36 ( 85%) of the females whose outcome was known achieved complete 
or partial response or improvement. Only (50%) of males achieved CR. By Chi 
squared test sex was an important factor in determining  out come with p value 
0.047.  
                  
                   
 FEMALES MALES 
NO 44 6 
MEAN 
25.27 26.67 
S.D 
7.44 4.46 
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        The outcomes according to gender is tabulated below 
                                  
                                               Table 5 
          
 
 
 
                 
                                        (Chi square p 0.047  df=1) 
 
                                               Figure 4 
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                                  DISEASE  DURATION  
                      The table below shows the distribution of duration of SLE at the 
onset of lupus nephritis. The mean duration of illness was 23.3 months. Range 
1moths to 84 months. 68% of patients presented within two years. 
                                 Table 6 
 
 
 
 
 
 
 
                     Mean disease duration in patients who have achieved complete 
response was 22.81 months while that of the refractory/death group was 33 
months[ Range 1-84 months in both groups]. Patients who achieved complete 
response had lesser disease duration of  SLE (10.19 months) before the onset of  
lupus nephritis than the other group. But this difference did not have any effect on 
the outcome. 
MONTHS FEMALE MALE TOTAL 
<12 18 3 21 
12—23 5 1 6 
24—35 7  7 
36—47 5 1 6 
48—59 4  4 
60—71 1 1 2 
72—84 4  4 
TOTAL 44 6 50 
45 
 
                                    PRESENTING SYMPTOMS  
The following was the distribution of presenting symptoms at the onset of 
lupus nephritis. Only 14 patients (28%)  presented with renal symptoms. In others 
lupus nephritis was asymptomatic and presented with extra renal symptoms. 
                                              Table 7      
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                       Among those who achieved some response (CR/PR/IMP) 12 
presented with renal symptoms and 26 with extra renal symptoms. By Chi square 
test the presenting symptom did not have any effect on the outcome.  
                                                   Table 8 
 
 
 
 
                             (Chi squared test p value 0.71 df  =1) 
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                                      EXTRA RENAL LUPUS 
The most common extra renal disease activity affecting the study group was   
neurologic involvement which was more in patients who were refractory or dead 
than those who achieved CR/PR though the difference was not statistically 
significant. Chi squared test p value- 0.27. 
                                                Table 9 
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                                            HYPERTENSION 
Number of   patients with hypertension was 16 ( 13 females, 3 males). The mean 
systolic & diastolic BP for CR group was 125.6 & 84 mmHg respectively while 
that of the refractory/death group was 137.25 & 92.5.Though by Chi squared test 
there was no significant difference between the group (p  Value 0.25 ). 
                                               Table 10 
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                                           COMORBIDITIES 
                  The following were the comorbidities seen.  
                                             Table 11 
S.No COMORBIDITY NUMBERS 
1 HYPERTENSION 16 
2 HYPOTHYROIDISM 8 
3 INFERTILITY 5 
4 DIABETES 3 
5 PULM.TB 3 
6 EXTRA PULM.TB 1 
7 OVARIAN TUMOR 2 
8 BENIGN ICT 1 
9 PREGNANCY 1 
10 POST PARTUM 1 
11 NEPHROLITHIASIS 1 
12 CATARACT 1 
13 INFECTIONS 3  
(osteomyl-1, 
skin-1, 
pneum-1) 
50 
 
  The independent samples test comparing the complete response group with the 
refractory /death group with respect to various clinical parameters is given below.  
Multistep logistic regression of the variables was also done.     
 
                                          Table 12      
 INDEPENDENT SAMPLE S TEST 
  t df Sig. (2-
tailed) 
     
AGE Assumed -1.019 38 .314 
 not assumed -1.090 11.778 .297 
DURATION Assumed -1.054 38 .298 
 not assumed -.842 8.731 .422 
SLEDAI  Assumed -3.132 38 .003 
 not assumed -2.304 8.270 .049 
Hb Assumed -.380 38 .706 
 not assumed -.318 9.055 .758 
PLATLET Assumed .222 38 .825 
 not assumed .232 11.416 .820 
S.ALBUMIN  Assumed .801 38 .428 
 not assumed .802 10.808 .440 
S.CREAT Assumed -2.727 38 .010 
 not assumed -1.891 8.000 .095 
GFR Assumed 2.870 38 .007 
 not assumed 3.433 14.124 .004 
ESR  Assumed .110 38 .913 
 not assumed .120 12.042 .907 
URINE 
PROTEIN 
Assumed -.599 38 .553 
 not assumed -.512 9.198 .621 
TIME TO 
CR 
Assumed -3.449 38 .001 
 not assumed -2.077 7.506 .074 
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                                              MULTI STEP LOGISTIC REGRESSION 
 B S.E. Wald df Sig. Exp(B) 
Step 1
a
 
AGE .276 .184 2.259 1 .133 1.318 
DURATIO .042 .040 1.087 1 .297 1.043 
SLEDAI .254 .115 4.876 1 .027 1.289 
Hb .437 .468 .870 1 .351 1.547 
PLATLET -2.280 2.043 1.246 1 .264 .102 
SALB 1.432 1.462 .959 1 .327 4.185 
CREATI -1.799 1.704 1.115 1 .291 .165 
GFRI -.158 .111 2.013 1 .156 .854 
ESR -.027 .040 .472 1 .492 .973 
ur_INITIAL .714 .730 .957 1 .328 2.043 
Constant -7.275 9.531 .583 1 .445 .001 
Step 9
a
 
AGE .158 .082 3.686 1 .047 1.171 
GFRI -.064 .025 6.607 1 .010 .938 
Constant -1.902 1.765 1.162 1 .281 .149 
a. Variable(s) entered on step 1: AGE, DURATIO, SLEDAI, Hb, PLATLET, SALB, CREATI, GFRI, ESR, ur_INITIAL. 
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                                           SLEDAI 
          The mean SLEDAI  was 19.78 (range 4-45). Mean SLEDAI for females was 
18.95 and for males 25.33. 
          In patients who achieved CR, mean SLEDAI was 17.94 (range 4-30). 
          In refractory/dead group the mean SLEDAI was 26.88 (16-45). 
          Using Independent samples test SLEDAI was an important factor defining 
the outcome [ p value 0.003].  
                                             Figure 9 
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 HEMOGLOBIN, PLATELET COUNT & SERUM ALBUMIN 
              The mean hemoglobin of the study group was 8.49 gm% (range 5-13.4).     
              The mean platelet count of the study group was 1.5lakhs/mm3.  No. of 
patients with platelet count less than 1 lakh was 9 out of 50.  
              The mean serum albumin value of the study group was 2.83g/dl (range 
1.6-3.9). 
               By independent samples test there was no statistically significant 
difference between the two groups with respect to hemoglobin, platelet count or 
serum albumin. Hence these factors did not influence the outcomes in this study. 
                   
  INITIAL PROTEINURIA: 
              The mean initial proteinuria for the CR group was 2.028 (0.3-5.7) and that 
of the refractory,dead group was 2.383(0.2-5.2). There was no statistically 
significant difference between the two groups.  
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                                  SERUM CREATININE 
                      The mean initial and final serum creatinine of the study group were 
1.35 mg% and 0.95 mg% respectively.  
                      The mean initial s.creatinine for the CR group was 1.216 mg% (0.7-
3.5) and that of the refractory,dead group was 2.275(range1.0-5). There was a 
statistically significant difference between the two groups. By independent samples 
test initial s.creatinine was found to be an important factor influencing the outcome 
( p value- 0.010). 
                                                      
                                                   Figure 10
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                                GLOMERULAR FILTRATION RATE 
               The mean initial and final GFR of the study group were 68.53 ml/min 
and89.09 ml/min respectively.  
               The mean initial GFR for the CR group was 75ml/min (16.8-135.8) and 
that of the refractory /dead group was 43.9 ml/min (14.7-74.4). There was a 
statistically significant difference between the two groups. By independent samples 
test initial  GFR was found to be an important factor influencing the outcome ( p 
value- 0.007). GFR was also an important factor in determining the outcome in 
multistep logistic regression (p = 0.01). 
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                               TREATMENT PROTOCOLS  
              Patients who were treated with cyclophosphamide under NIH or ELNT 
protocol, azathioprine and MMF achieved 80%, 75%, 100%, 80%  response 
respectively.The treatment protocols used for the induction of treatment did not 
influence the outcomes.  
                                                    Table 14              
 
  
 
 
                                     Chi squared test ‗p‘ value 0.37. 
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                                       BIOPSY CLASS 
         Biopsy was not done in 3 patients due to unwillingness. The following is the 
break up. Class IV was the commonest type (45%) followed by class III (15%) and 
class II &V (13% each). 
                                                  Table 15 
 CR PR IMP REF DEATH  LOST TOTAL 
CLASS I 
       CLASSII 
6 
     
6 
CLASSIII 
4 
 
1 1 
 
1 7 
CLASSIV 
12 2 1 4 1 1 21 
CLASSV 
5 
  
1 
  
6 
CLASSVI 
       CLASSII/V 
1 
 
1 
 
1 
 
3 
CLASSIII/IV 
1 
     
1 
CLASSIII/V 
1 
     
1 
CLASSIV/V 
  
1 
   
1 
CLASSIV/VI 
1 
     
1 
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                Using Chi squared test there was no significant difference between the 
outcomes of patients with proliferative type as compared to the membranous type 
(p  value 0.44). 
                                                  Table 16 
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 IMMUNOLOGIC PROFILE 
                     All the patients were ANA positive. .Anti ds DNA antibody was done 
in 29 patients. It was positive in 25 (19 achieved CR/PR/IMP; 4 were refractory or 
dead,2 LTF). It was negative in 4 (all achieved CR/PR/IMP). 
                     Of those patients for whom antidsDNA antibodies, anticardiolipin 
antibodies, C3 and C4 were done there was no statistically significant influence on 
the final outcomes.  
                                              
                                                 Table 17  
 
 
 
 
 
 
 
 CR/PR/IMP REF/DEATH p value 
dsDNA pos 19 4 0.88 
 dsDNA neg 4 0 
ACL pos 4 0 1.00 
ACL neg 8 5 
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                      COMPLEMENT LEVELS AND OUTCOME 
                                                 Table 18 
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CORRELATION BETWEEN VARIOUS FACTORS AND COMPLETE 
RESPONSE 
In those patients who achieved complete response the following correlations were 
made with time taken to achieve complete response. 
                                                 Table  19 
 CORR.COEFF p VALUE N value 
AGE 0.08 0.85 32 
DURATION -0.02 0.8 32 
SLEDAI 0.13 0.4 32 
HEMOGLOBIN -0.02 0.9 32 
PLATELET -0.18 0.25 32 
S.ALBUMIN -0.01 0.9 32 
INITIAL 
CREATININE 
0.35 0.02 32 
GFR INITIAL -0.13 0.39 32 
ESR 0.04 0.798 32 
URINE PROTEIN 0.09 0.55 32 
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                   Mean time taken to achieve complete response was 9.75 months (range 
3-24 months). 
AGE :         There was small but not significant correlation between age and time 
taken to complete response (correlation coefficient 0.08 ). 
DURATION OF ILLNESS: There was a negative correlation between duration of 
illness and time to achieve complete response.  
SLEDAI : There was a positive correlation between SLEDAI and time taken to 
complete response (correlation coefficient +0.132). 
                  There were small negative correlations between hemoglobin level, 
platelet count and serum albumin (correlation coefficients -0.19,-0.183,-0.01 
respectively). 
SERUM CREATININE: 
                   There was a strong positive correlation between serum creatinine and 
time taken to complete response (correlation coefficient +0.353, p value 0.026). 
Hence higher the creatinine value  longer was the time taken to achieve complete 
response. 
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             GFR levels had a negative correlation with time taken to complete 
response (correlation coefficient -0.138) and initial urine protein levels had a small 
positive correlation (correlation coefficient +0.09). 
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                                      DISCUSSION 
                    Lupus nephritis is one of the major manifestations determining the 
course of illness in patients with SLE. A number of studies have found a good 
correlation between clinical data and outcomes in LN while others have not. 
                       In the present study the outcome of complete response was achieved 
in 32 patients (64%), partial response in 2 patients (4%) and improvement in 4 
patients (8%).  Six patients (12%) were refractory to treatment; 2 patients died 
(4%); follow up was lost in 3 patients and in one patient the final outcome could 
not be assessed. 
                       The percentage of patients who achieved complete response was 
similar to the study by Senija et al. 
50
But this was a long term study with average 
follow up period of 10.9 years. In a short term Indian study 64% achieved CR or 
PR at one year. 
62
 In another study 
42
 CR was achieved in 43% with mean time 
taken to achieve CR was 18 months whereas in our study the time taken to achieve 
CR was 9.75 months .The time taken to achieve CR was 4.5 ±1.9 months in the 
above mentioned Indian study.  
                      The differences in outcome and time taken to achieve CR could be 
explained by racial and genetic differences to therapy. A study published in India  
has concluded that if standard immunosupression is given the outcome of LN is 
65 
 
reasonably good.
61
 Studies published in India among pediatric patients have also 
supported this notion. In a study from AIIMS 
65
 84.6 % achieved complete or 
partial response in one year and 15.4% were refractory. In another study from 
CMC Vellore 
66
 70% achieved remission in 18.8 months and 7.5 % died. 
                      Average age of patients who achieved CR was 3 years lower than  
(statistically significant)  those who remained refractory or dead . Previous study 
by Austin 
47
and collegues concluded that age more than 30 years is associated with 
worse outcome. On the contrary in another study 
44
 age less than 29 years was 
associated with poor outcome. Higher age may be associated with poor renal 
function, decreased serum albumin, increased ESR and proteinuria and 
comorbidities like hypertension and diabetes . 
                      The importance of sex as a prognostic factor influencing the outcome 
has been studied before. 
47 
In one study female sex was associated with worse 
prognosis while in another study by Faurschou M 
53 
male sex was associated with 
poor prognosis. In India a study by Soni et al 
67
found statistically significant 
difference between male and female patients with LN with regards to renal 
function and activity index (poorer in males). In our study also there was a 
statistically significant difference between males and females in achieving 
complete or partial response with males faring poorly. The reason may be due to 
males having higher disease activity.
73
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                      As acknowledged world wide 
62
 majority of the patients in our study 
(72%) did not present with symptoms pertaining to renal involvement. LN was 
diagnosed during routine investigations. But this factor did not influence the final 
outcome as almost all patients with abnormal urine examination underwent renal 
biopsy in our set up regardless of their presenting symptoms. 
                     Major extra renal disease activity affecting the outcome was 
neurologic involvement and was seen in 40 % of patients.  Neurologic involvement 
was more in patients who were refractory or dead though the value was not 
statistically significant. 
                      Primary infertility, problems with pregnancy and post partum state, 
ovarian tumors were seen in 9 female patients. As seen in other Indian studies 
61, 62
  
the most common complication of therapy was infections (14%) . These along with 
socioeconomic constraints hampered the therapeutic decision making as typical of 
any developing country. 
                      The mean SLEDAI of patients achieving CR was lower than that of 
patients who remained refractory or died (statistically significant). Also higher 
SLEDAI correlated positively with delay in achieving remission. This result was 
similar to that of a study by James Tumlin 
44
 whereas in the study by Sircar et al 
62 
there was no significant correlation between SLEDAI and outcomes. 
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                     There was no statistically significant difference between the mean 
hemoglobin level between the two groups in contrast to some studies. 
53
 This could 
be explained by the fact that anemia is grossly prevalent in Indian women (51%)
 74 
hence it is not surprising that women with SLE and LN are anemic. But using 
correlation coefficient patients with low hemoglobin were found to take longer 
time to achieve complete response. Similar results were seen with low platelet 
counts and serum albumin, high ESR and initial proteinuria. 
                      An important observation made was that more number of patients in 
CR/PR group (27) were normotensive while 11 had hypertension though this did 
not affect the final outcome. 
                       As seen in earlier studies 
42, 53, 61
 higher initial serum creatinine and 
lower GFR were poor prognostic factors influencing the outcomes (statistically 
significant difference between the two groups). Also high serum creatinine at onset 
of illness significantly affected the time taken to achieve complete response.   
Initial GFR value also correlated negatively with time taken to achieve CR though 
in some studies there is no correlation between outcomes and GFR. 
62
 
                      There was no significant association between anti ds DNA and ACL  
antibody positivity and hypocomplementemia and the outcomes. But as mentioned 
68 
 
earlier they were done only in few patients due to technical and financial 
constraints which could have skewed the results. 
                     Analysing the treatment protocols used for induction treatment 75-
80% of  those patients who were started on MMF/ cyclophosphamide under ELNT 
or NIH protocol achieved CR/PR or improved. Under the recent guidelines issued 
by EULAR/ERA-EDTA 
34
, MMF has emerged as the treatment modality of choice 
in patients with class III/IV/V LN due to favorable toxicity profile. 11 of 16 (69%) 
patients who achieved response under NIH protocol belonged to class IV and 4 of 
6 (66%) patients who achieved response under ELNT protocol belonged to class 
IV. 
                  So in our set up cyclophosphamide under ELNT or NIH protocol are 
equally effective in class IV LN. When ELNT protocol was originally initiated in 
young European women with LN who did not have adverse prognostic factors, it 
was thought that it might not be suitable for patients of other races with poor 
prognostic features. But 10 years down the lane recently long term results of ELNT 
have been published which show that outcomes like ESRD and death did not differ 
much in patients treated under this protocol from those who received conventional 
treatment.
75 
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                   In this study apparently all the ten patients who received azathioprine 
as induction treatment achieved CR/PR or improved while none was refractory. 
This may be quiet surprising in the context of recent findings which have shown 
that patients initiated on azathioprine as induction treatment for proliferative LN 
have produced poorer outcomes. But on close analysis it can be found that 50% of 
our patients started on azathioprine belonged to class II (all achieved CR), where it 
was used as a steroid sparing agent. In one patient biopsy was not done and with all 
probability that she may belong to class II, she was treated on clinical grounds. 
While one patient improved and another achieved only partial response, 2 patients 
each belonging to class IV and V achieved CR. 
                   Analyzing the histologic class, as seen in other parts of the country 
class IV LN is the commonest histologic class seen in this study. Previous studies 
regarding the role of histologic class influencing the outcome of nephritis have 
been controversial. In the study by Faurschou et al 
53
diffuse proliferative glomerulo 
nephritis strongly correlated with the outcome of ESRD while in Indians in a study 
by Dhir et al
61
 no difference in survival based on histologic class was found. 
Among Indian children also there are studies which showed no correlation between 
histologic class and end results like ESRD/ death. In this study also there was no 
relation to outcome and histologic class.  
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                    Among patients who achieved CR, four patients (12.5%) flared-3 
patients had nephritic flare and one patient had proteinuric flare. This is slightly 
higher than that observed in an Indian study (7.7%).
62 
In one of these patients (a 
female patient of class IV LN) the dose of immunosuppression was increased and 
the patient continued to be in CR. In another patient repeat biopsy showed a class 
switch from IV to VI. He rapidly progressed to ESRD, had persistent extra renal 
activity and died. The second patient who died even before treatment could be 
initiated was a female, of class II/V LN and had severe extra renal activity. The 
third patient (class II LN) with nephritic flare was being planned for repeat biopsy 
at the time of completion of study. In one female patient with proteinuric flare, the 
maintenance immunosuppression  was changed from  azathioprine to MMF and the 
patient continues to be in CR. 
                     One patient who achieved CR at 6 months lost follow up there after. 
One patient who was initially refractory to MMF responded to cyclophosphamide 
after repeat biopsy showed the same class (classIV) and she achieved CR at the 
end of the study period.In those patients who remain refractory at the end of the 
study period treatment decisions have been hampered by socio economic 
conditions like presence of pregnancy, desire to conceive and the cost of 
alternative therapy. 
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CONCLUSION 
1. Among fifty patients 64% achieved complete response,4% achieved partial 
response , 8% improved while 12% remained refractory and 4% died. 
2. Lower age, female sex, lower disease activity, good initial renal function (low 
s.creatinine, high initial eGFRwere important factors associated with favourable 
outcome. 
3. Presenting symptoms, disease duration, extra renal disease activity, presence of 
hypertension, haemoglobin, platelet counts, serum albumin levels, treatment 
protocols and biopsy class did not significantly influence the outcome. 
4. Among patients who achieved complete response initial serum creatinine 
positively correlated with time taken for outcome (statistically significant). 
5. Higher age, disease activity, ESR and initial proteinuria positively correlated 
with time taken to complete response (not statistically significant). 
6. Hemoglobin, platelet count, albumin, GFR showed negative correlation with 
time to complete response (not statistically significant).   
7. In south Indian patients long term studies are needed to analyze the correlation 
between clinical features and outcomes in lupus nephritis. 
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URINE PROTEIN
CREAT GFR I CREAT GFR II BIOPSY INITIAL FINAL INDUCT MAINT OUTCOME FOLLOW UP TIME TO CR
1 53467 27 F 12 45 5.9 2 180 120 1.6 1.2 55.58 1.3 55.3 classIV 1.86 1.56 CYC(elnt) AZA REF 24
2 54129 29 F 84 27 8.8 1.89 140 90 2.7 2 31 classV/II 5.2 DEATH 0.25
3 54495 21 F 72 17 9.1 1.72 100 70 3.7 0.9 109.7 0.8 120 classIV 2.4 0.4 CYC NIH CR 24 6
4 54083 24 F 6 9 9 1 120 80 3.4 1.2 50.21 classIV 3.7 CYC(elnt) AZA LOST 2
5 54112 29 F 3 7 10.2 1.68 110 80 2.8 1.1 59.6 0.8 81.9 classIII 2 0.03 AZA AZA CR 22 6
6 54576 28 F 36 25 9.8 2.1 120 80 3.2 0.8 82.6 0.8 82.6 classIII/IV 4.3 0.08 CYC NIH CR 18 6
7 54297 22 F 12 25 6.3 0.95 100 70 3.2 1 83.58 1 89.2 classIV 2.6 0.4 CYC NIH AZA CR 20 12
8 54056 25 F 2 29 9.3 1.75 120 80 3.7 2.2 30.2 0.7 107 classII 0.28 0.08 AZA AZA CR 24 6
9 52987 38 F 24 9 11 1.93 120 80 3.9 0.7 89.5 0.7 89.5 classII 0.3 0.05 AZA AZA CR 24 6
10 54182 16 F 2 11 10.6 2.18 110 80 1.8 1 67.35 0.8 84.2 classIII 2.6 0.05 CYC(elnt) AZA CR 22 6
11 55650 30 F 7 15 6 0.67 150 110 3.4 1.4 51.2 0.7 107.6 classIV 0.7 0.08 CYC NIH CR 3 3
12 46585 20 F 48 14 5 2.35 110 60 2.1 1.2 53.1 0.8 70 classIII/V 0.8 0.03 CYC(elnt) AZA CR 24 6
13 50098 18 F 36 18 5.2 0.8 150 110 2 3.5 18 0.8 99.02 classIV 3.5 0.2 CYC (elent MMF CR 24 12
14 46094 41 F 72 12 10.6 1.6 120 80 2.2 1.1 74.38 1.4 61.38 classIV 2.5 2.3 MMF REF 24
15 54623 26 F 5 11 9.8 1.62 90 60 3.5 1 67.3 1.2 60.22 classIII 0.75 0.75 CYC NIH AZA REF 13
16 50329 30 M 60 14 7 2.5 160 110 3.7 0.9 135.8 1 128.33 classIV 3.95 0.03 CYC NIH CR 24 24
17 51487 20 F 24 19 9.8 1.62 110 70 3.8 0.7 101 0.7 109 classIII 2.7 0.35 MMF CR 24 12
18 55432 19 F 36 26 5 1.62 150 110 2.3 3.4 16.81 0.7 89.79 classIV 0.5 0.07 CYC NIH CR 24 12
19 55860 22 F 12 38 9.8 1.7 130 80 1.8 3.3 27.3 1.3 75 classIV/VI 0.67 0.2 CYC /NIH CR 24 6
20 49810 37 F 48 12 9.4 1.78 160 100 3.2 0.9 94.58 0.9 99.9 classII 0.7 0.3 AZA AZA CR 24 6
21 53456 17 F 12 21 10.2 1.76 110 70 3.5 1.1 52.8 0.8 79.6 classIV 1.5 0.03 CYC(elnt) AZA CR 18 6
22 55096 19 F 2 19 10.2 1.82 120 70 3.2 0.9 63.49 0.8 80.35 classIII 0.5 0.05 CYC NIH CR 12 6
23 55123 19 F 24 23 6.9 1.52 110 80 2 0.8 73.21 0.7 87.75 classV 2.1 0.3 MMF MMF CR 12 12
24 53976 24 F 18 6 6.2 0.88 120 80 3.4 0.8 85.8 0.8 116.7 classIV 4 3.1 MMF IMP 4
25 55705 23 F 3 19 7 1.52 120 90 2.7 1.2 57 not done 5.4 AZA AZA LOST 2
26 54104 23 F 24 17 9.8 1.75 110 70 2.4 1 69.2 0.8 93.23 classIV 3.3 1.6 AZA AZA PR 18
27 55360 24 F 6 25 9 1.15 110 80 2.2 0.8 77.03 0.8 85.89 classV 5.7 0.4 CYC NIH CR 10 6
28 54615 23 M 4 23 9.7 2.58 120 70 2.7 0.9 124 0.8 120.8 classIV 1.6 0.07 CYC NIH CR 18 6
29 55930 18 F 1 20 10.8 0.9 120 80 2.5 0.7 72.1 0.7 78.9 classIII 1.21 1 MMF IMP 3
30 54883 24 M 12 29 8.6 1.4 170 110 1.4 1.1 96.7 not done 1.9 CYC NIH CANT BE ASSESD 13
31 53104 26 M 36 25 13.4 1.85 150 100 2.2 3.9 21 3.6 26.3 classIV 3.75 3 CYC NIH REF 24
32 53199 34 M 4 39 6.6 1.8 100 70 2.5 5 14.72 classIV 0.2 CYC NIH DEATH 24
33 49876 19 F 84 14 5.5 1.45 150 100 3.5 1.5 55.4 0.9 101.5 classIV 1.4 0.04 CYC(elnt) AZA CR 24 6
34 48248 26 F 36 12 9.8 1.64 120 80 2.8 1.1 80.4 1 99.59 classV 1.5 0.07 CYC NIH CR 24 6
35 47628 20 F 48 28 7.1 1.65 190 120 3.4 1.5 45.33 1.6 44.27 classIV 0.7 0.6 CYC (eint) MMF REF 24
36 53476 47 F 24 20 9 1.4 150 100 2.4 0.7 100.3 0.6 124.5 classII 0.6 nil AZA AZA CR 15 12
37 55306 27 F 5 4 5.5 1.02 120 80 3.5 0.8 96.75 0.8 103.6 classIV 2.5 0.07 CYC NIH AZA LOST 18
38 51641 41 F 7 12 10.2 1.49 170 100 3 1.5 54.4 1 86.49 classIV/V 4 3.1 CYC NIH IMP 3
39 55723 18 F 36 16 8.2 1.4 100 70 3 1.6 39.1 1 69.13 classII/V 2 1.5 AZA IMP 3
40 54738 36 F 24 24 8.5 1.8 110 80 2.1 0.9 76.14 0.8 92.8 classII 1.06 0.04 AZA CR 24 12
41 48934 30 F 24 22 6.6 2.98 120 80 2.8 1.1 66.1 0.7 111.3 classIV 3.3 0.03 CYC NIH CR 24 12
42 46800 20 F 1 25 6.8 1.5 150 100 2.5 0.9 100.74 0.8 116.8 classII/V 2.95 0.03 MMF CR 24 12
MASTER CHART
S.No RCC AGE SEX DURATION SLEDAI Hb PLATELET SYS.BP
TRAETMENT FINAL
DIAS BP ALBUMIN
INITIAL FINAL
URINE PROTEIN
CREAT GFR I CREAT GFR II BIOPSY INITIAL FINAL INDUCT MAINT OUTCOME FOLLOW UP TIME TO CRS.No RCC AGE SEX DURATION SLEDAI Hb PLATELET SYS.BP
TRAETMENT FINAL
DIAS BP ALBUMIN
INITIAL FINAL
43 55940 21 F 4 23 7.9 1.8 100 70 3.5 0.9 62.44 0.7 88.31 not done 0.8 0.08 AZA CR 3 3
44 53486 24 F 1 35 8.7 0.9 120 80 2.5 0.8 99.28 0.7 106.82 classV 2.5 0.18 CYC NIH CR 24 24
45 54486 38 F 3 11 9.3 1.6 110 80 3.5 0.7 99.77 0.7 110.1 classV 2.6 0.02 AZA CR 24 24
46 47856 23 F 3 16 7 0.4 130 100 3.3 2.1 42.1 1.8 50.65 classV 4.1 2 CYC NIH AZA REF 24
47 55654 23 M 4 25 9 0.9 110 70 2.5 0.9 83.67 classII 2.7 AZA LOST 2
48 47997 25 F 48 14 9.8 1.86 180 120 1.8 1.1 67.88 1.1 70 classIV 1.3 0.15 CYC NIH CR 24 18
49 55647 21 F 6 20 10.2 0.62 120 80 3.4 0.9 84.29 0.8 101.85 classII 5 0.12 LOW STEROID CR 17 6
50 46787 17 F 60 19 9.8 2 120 80 3.5 0.8 72.6 0.7 95.42 classIV 1.5 0.6 CYC ELNT AZA PR 18
Age-Years, Duration- Months, Hb- grams%, Platelet- L cumm, BP-mmHg, Albumin- gm%, Creatining- mg%, GFR-ml/min, Proteinuria-gm/day, Followup, time to CR- Months
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INTRODUCTION Sytemic lupus erythematosus is a paradigmatic autoimmune disorder, the
manifestations of which are protean sparing few organ systems if any.1 Such diversity is attributed to
its etiopathogenesis wherein antibodies to the components of cell nucleus have been implicated. One
major cause of morbidity and utilization of health resources is renal involvement. More than half of the
mortality in SLE is due to renal involvement.2-5 As with SLE, heterogeneity, both clinical as well as
histological is the hall mark of lupus nephritis. The disease usually is asymptomatic in its earlier
course thus vigilant screening of SLE patients for renal involvement remains the important step in...
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